H ypercholesterolemia, a well-known risk factor for cardiovascular diseases, is associated with disorders of the short-term and long-term regulation of blood pressure (BP) 1 and heart rate (HR) 2 that may precipitate cardiovascular events. 3 Indeed, an increase in BP variability and, conversely, a decrease in HR variability both are predictive of increased cardiovascular morbidity and mortality. 4 In particular, several studies emphasized the negative prognostic value of enhanced BP variability toward end-organ damage, even independently of average BP levels. 4, 5 The activity of the parasympathetic and sympathetic nervous systems is the main determinant of BP and HR homeostasis through its modulation of the arterial baroreflex. In addition, recent work identified the role of vascular nitric oxide (NO) as a second short-term buffering mechanism in response to increases in arterial BP. 6 Accordingly, mice with a genetic deletion of the endothelial NO synthase, or eNOS, have both elevated average BP levels 7, 8 and increased BP variability, 9, 10 as observed in other animal models after pharmacological NOS blockade. 9 Numerous studies have demonstrated that hypercholesterolemia is associated with defects of the NO-dependent endothelial function, including in genetically dyslipidemic, apolipoprotein (apo) E-deficient mice. 11 The correlation between NOS function and HR or BP variability in this mouse strain, to the best of our knowledge, has never been examined.
We therefore studied BP and HR variabilities, as well as their modulation by NOS and the autonomic nervous system, in hyperlipidemic, apoE Ϫ/Ϫ mice by telemetry. These measurements were correlated with the expression, in cardiac and aortic tissues, of caveolin-1, a structural protein of caveolae, that acts as an allosteric inhibitor of eNOS, thereby reducing its ability to produce NO. 12, 13 Finally, we studied the effect of a chronic treatment with the HMG-CoA inhibitor rosuvastatin on these parameters.
Methods

Animals and Telemetric Recordings
Male apoE-deficient and control mice of the same genetic background (C57Bl/6; 6 to 8 weeks old; Charles River UK, Ltd, Margate, UK) were treated with rosuvastatin (supplied by AstraZeneca UK; 80 mg · kg Ϫ1 · d Ϫ1 PO) or placebo for 2 weeks. The dose of rosuvastatin was chosen according to preliminary lipid-lowering experiments in apoE Ϫ/Ϫ mice and to maximize the potential for peripheral (as opposed to hepatic) pharmacodynamic effects. Animals were kept on a 12-hour light/dark cycle. BP signals (and HR, derived from pressure waves) from the aortic arch were measured in conscious, unrestrained animals with surgically implanted, miniaturized telemetry devices (Datascience Corp). After 2 weeks of recovery, short-or long-term (24 hours) online recordings were digitized (range, 20 to 2000 Hz) and stored for further analysis. Measurements were repeated after rosuvastatin treatment (or placebo) in the same mice.
In all mice, the acute effects of atropine (1 mg/kg) and of a nonselective NOS inhibitor (N G -nitro-L-arginine methyl ester, or L-NAME; Sigma; 30 mg/kg) were tested after intraperitoneal injection and subsequent recording for 15 minutes.
All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Spectral Analysis of HR and BP Variabilities
Spectral analysis using a fast Fourier transformation algorithm on sequences of 512 points was performed by use of the HEM 3.4 software (Notocord Systems) on BP and HR recordings. The area under the curve was calculated for the very-low-frequency (VLF: 0.05 to 0.4 Hz), low-frequency (LF: 0.4 to 1.5 Hz), and highfrequency (HF: 1.5 to 5.0 Hz) bands, as previously defined in the mouse species. 10, 14 Spectral variability at each bandwidth was normalized to the total spectral area.
Immunoblotting Experiments
Equal amounts of cardiac and aortic protein extracts were processed for Western blot analysis as described by Feron et al 12, 15 with monoclonal anti-eNOS and anti-caveolin-1 antibodies (BectonDickinson). Densitometric signals were normalized by the immunoblotted signal for the chaperone protein hsp90 on the same filter. We previously verified that treatment with a statin has no effect on hsp90 expression in cultured cells 16 or in tissue extracts with rosuvastatin in the present study. Normalized results are expressed as percentage of mean densitometric values of control (C57Bl/6) tissues on the same blot.
Statistical Analysis
All results are expressed as meanϮSEM. All statistical comparisons were performed by use of Student's t test or 1-way ANOVA where appropriate. A probability value of PϽ0.05 was considered significant. In control (C57Bl/6) mice, continuous (24 hours) BP and HR recordings revealed a typical variation during the light-dark cycle, ie, light (corresponding to a resting period in mice) values of systolic BP (SBP), diastolic BP (DBP), and HR were significantly lower than dark (activity period for mice) values. By contrast, circadian variations of HR, SBP, and DBP were totally abolished in untreated apoE Ϫ/Ϫ mice ( Figure  1 , A, C, and E, and Two weeks of treatment with rosuvastatin had no significant effect on HR, SBP, or DBP values in control mice but reduced all parameters in apoE Ϫ/Ϫ mice to control levels (412Ϯ5.6 bpm, 104.1Ϯ1.4 mm Hg, and 77.2Ϯ1.0 mm Hg, respectively). Figure 1 , B, D, and F, shows that rosuvastatin also restored the circadian variations of these parameters in apoE Ϫ/Ϫ mice. Figure 2C shows that apoE Ϫ/Ϫ mice had decreased HR variability in the HF band, revealing defects in their parasympathetic control.
Results
ApoE
Treatment with rosuvastatin had no influence on these parameters in control mice. In apoE Ϫ/Ϫ mice, rosuvastatin normalized SBP and HR variabilities in the VLF band, as well as HR variability in the HF band ( Figure 2C , hatched bars).
؊/؊ Mice Have Impaired Sensitivity to Atropine and NOS Inhibition That Is Restored by Rosuvastatin
The integrity of the vagal efferent and of the NOS pathways, 2 main determinants of HR and SBP variabilities, was assessed in all groups of animals by acute challenge with either the muscarinic cholinergic antagonist atropine or the NOS inhibitor L-NAME under telemetric monitoring in the awake state.
The effects of atropine on absolute HR and HR variability are shown in Figure 3 . In C57Bl/6 mice, atropine dramatically increased HR ( Figure 3A ) but reduced HR variability in the HF and LF bands ( Figure 3B ) and decreased HR variance ( Figure 3C ), as expected. In apoE Ϫ/Ϫ mice, atropine induced much smaller changes in absolute HR ( Figure 3A ) and HR variance ( Figure 3C ). Of note, rosuvastatin (which had no effect in control animals) improved HR variance ( Figure 3C , hatched bars) and restored HR response ( Figure 3A , hatched bars) to atropine in apoE Ϫ/Ϫ mice. The effects of acute NOS inhibition are shown in Figure 4 . In control C57Bl/6 mice, NOS inhibition resulted in an increase in SBP ( Figure 4A ) and an increase in SBP variability in the VLF band ( Figure 4 , B and C), as expected. In apoE Ϫ/Ϫ mice, NOS inhibition produced much smaller changes in SBP ( Figure 4A ) and SBP variability in the VLF band ( Figure 4C ).
Again, rosuvastatin (which had no effect in control mice) increased the absolute SBP change ( Figure 4A ) and SBP variability response ( Figure 4C , hatched bar) to NOS inhibition in apoE Ϫ/Ϫ mice ( Figure 4 , A and C, hatched bars).
ApoE ؊/؊ Mice Have Increased Cardiac and Aortic Caveolin-1 Abundance That Correlates With SBP Variability
In apoE Ϫ/Ϫ mice, the impaired sensitivity to NOS inhibition suggested alterations in NOS abundance, activity, or both. We quantified the expression of eNOS protein and of one key eNOS allosteric inhibitor, caveolin-1, in whole extracts of cardiac and aortic tissues from all groups of animals. ApoE Ϫ/Ϫ mice had levels of immunoblotted eNOS similar to those in control animals. Rosuvastatin had no effect on eNOS abun-dance in either group of mice (not shown). As shown in Figure 5 , caveolin-1 levels were increased by 2-fold in cardiac and aortic extracts of apoE Ϫ/Ϫ mice ( Figure 5 , A and B). Rosuvastatin had no effect on caveolin-1 levels in C57Bl/6 mice but reduced caveolin-1 abundance to control levels in heart and aorta of apoE Ϫ/Ϫ mice ( Figure 5 , A and B, hatched bars).
Of note, parallel measurements of plasma lipid levels in the same animals revealed that plasma LDL cholesterol concentration remained elevated in rosuvastatin-treated apoE Ϫ/Ϫ mice (386Ϯ101 versus 557Ϯ47 mg/dL; PϭNS), as expected from previous experiments with rosuvastatin in this mouse strain.
Because caveolin-1 is a main regulator of eNOS activity in conduit arteries such as the aorta, we examined the correla- tion between aortic caveolin-1 levels and SBP variability in the VLF band, reflective of the NO buffering effect on BP (see Figure 4) , across all groups of animals. A strong positive correlation (yϭ5.25xϩ47.5, r 2 ϭ0.80) was observed between these 2 measures, as illustrated in Figure 6 .
Discussion
Abolition of circadian cycles of BP and HR in hypertensive animals, 17 such as apoE Ϫ/Ϫ mice in the present study (Table and Figure 1 ), have been generally associated with dysfunctions of the parasympathetic and/or sympathetic components of the arterial baroreflex. 18 Using spectral analysis of BP and HR variability, several groups have identified the influence of neurohumoral or autonomic input on specific frequency bands of the variability spectra. The bandwidth characteristic of each component varies among animal species and was recently determined in mice. 10, 14 We independently validated the influence of the parasympathetic component and of the NO pathway on our spectra using acute pharmacological inhibition with atropine and an NOS inhibitor, respectively. In control mice, we found that HR variability in the HF band was abrogated by atropine ( Figure 3B ), confirming its dependence on a functional parasympathetic system. In apoE Ϫ/Ϫ mice, we then observed a basal (ie, without atropine) reduction of HR variability in this HF band ( Figure 2C ), suggesting a defective parasympathetic drive to the heart. In support of this interpretation, atropine had no further effect on HR variance in apoE Ϫ/Ϫ mice ( Figure 3C ). Similar attenuated responses to atropine challenge have been observed in obese hypertensive dogs 17 that exhibit altered resting and reflex parasympathetic control of HR.
HR and BP variabilities in the VLF band reflect the mixed influence of neurohumoral mechanisms. In addition, SBP variability in the VLF band also integrates the short-term buffering effect of NO. 9 Accordingly, in our control mice, NOS inhibition increased SBP and its variability in the VLF band ( Figure 4, A  and B) . A similar higher BP variability in the VLF band is distinctively observed in mice genetically deficient in eNOS. 9 In apoE Ϫ/Ϫ mice, SBP variability was markedly increased in the VLF band (Figure 2A) , suggesting a defective NO control mechanism. Again, the effect of NOS inhibition on SBP ( Figure  4A ) and SBP variability in the VLF band ( Figure 4C ) was 
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significantly attenuated in apoE Ϫ/Ϫ mice, consistent with constitutive impairment of their NO buffering system. In addition, because endogenous NO has been implicated in the modulation of the parasympathetic input to the heart at the presynaptic 19 and postsynaptic 20 -22 levels, respectively, a defective cardiac NOS may also participate in the loss of HR variability in the HF band (as shown above) irrespective of the vasculature.
High LDL cholesterol can impair eNOS-dependent endothelial function (and subsequently increase SBP variability) in conduit arteries through a variety of mechanisms, some of which are specifically targeted by statin treatment. 23, 24 Notably, some previous studies in apoE Ϫ/Ϫ mice have found altered NOdependent vasodilatation only at later stages of atherosclerosis development. 25, 26 They did not examine intermediate time points closer to the Ϸ3 months used here. Yang et al, 26 for example, found increased BP and impaired cutaneous hyperemia to mustard oil application at 7.5 months but not 6 weeks of age. However, the neurogenic vasodilatation to mustard oil is less specific for endothelial eNOS function, 27 and the sensitivity of their BP recordings 24 hours after catheter implantation may have been hampered by residual effects of anesthesia/surgery, as previously demonstrated. 28 In addition to changes in eNOS expression, alterations in eNOS-dependent vasodilatation may involve posttranscriptional regulation of the activity of the enzyme through allosteric interactions with other proteins, such as the caveolar coat protein, caveolin-1, that represses eNOS activation. 13, 29 The functional relevance of these protein-protein interactions in vivo is best illustrated by the phenotype of caveolin-1-deficient mice, which exhibit a vascular hyporesponsiveness to vasoconstrictor agonists because of de-repressed eNOS activity. 30, 31 Conversely, eNOS activity is impaired on increased expression of caveolin-1 in endothelial cells, such as obtained on exposure to native LDL cholesterol. 12 In addition, oxidized LDL particles may also independently alter eNOS abundance 32 or subcellular localization. 33 In our hands, the effect of native LDL on caveolin-1 was fully reversed on inhibition of Ϫ/Ϫ and C57Bl/6 mice with (C57 R, gray bars; apoE R, hatched bars) or without (C57, black bars; apoE, white bars) rosuvastatin treatment (nϭ6 in each group). Tachycardic effect of atropine is selectively lost in apoE Ϫ/Ϫ mice and restored to control levels after 2 weeks of treatment with rosuvastatin. PϽ0.05 vs baseline in *C57, $C57 R, and #apoE R. B, Representative power spectra of HR variability (HRV) before and after atropine administration in a C57Bl/6 mouse. Note decrease in HRV across whole HF band after atropine (bold tracing), reflecting loss of parasympathetic control of HR. C, Absolute changes in HRV induced by atropine in apoE Ϫ/Ϫ and control mice, with or without rosuvastatin treatment (same labels as in A). *PϽ0.05 vs C57, C57 R, and apoE R. Hypertensive effect of L-NAME is selectively lost in apoE Ϫ/Ϫ and restored to control levels after 2 weeks of treatment with rosuvastatin. PϽ0.05 vs baseline in *C57, $C57 R, and #apoE R. B, Representative power spectra of SBP variability before and after L-NAME administration in a C57Bl/6 mouse. Note selective increase in SBP variability in VLF band after L-NAME (bold tracing). C, Absolute change in VLF energy band of SBP variability induced by L-NAME administration in apoE Ϫ/Ϫ and control mice before and after 2 weeks of treatment by rosuvastatin (same labels as in A; nϭ6 in each group). *PϽ0.05 vs C57Bl/6, C57 R, and apoE R.
cholesterol synthesis in endothelial cells with a statin. 15 We therefore examined the possibility that hemodynamic alterations in dyslipidemic, apoE Ϫ/Ϫ mice were associated with similar changes in caveolin-1 and/or eNOS abundance that would be sensitive to chronic treatment with rosuvastatin. We found that caveolin-1 content was increased in aortic and cardiac tissues of apoE Ϫ/Ϫ mice (compared with C57Bl/6 controls; Figure 5 ), whereas eNOS abundance was unchanged. The abundance of aortic caveolin-1 also positively correlated with increased variability of SBP in the VLF band (Figure 6 ), suggesting the negative functional impact of caveolin-1 upregulation on the buffering capacity of eNOS on SBP. The notion that these expressional changes in aortic caveolin-1 may have an impact on NOS function in apoE Ϫ/Ϫ mice in vivo is supported by the insensitivity of these animals to the NOS inhibitor ( Figure 4 , A and C). Under our treatment conditions, rosuvastatin did not alter eNOS expression but reduced caveolin-1 expression to control levels ( Figure 5 ). The statin also restored the effect of NOS inhibition in the same animals, suggesting a restoration of NOS function even in the absence of changes in eNOS abundance.
Consistent with the previous identification of sterol regulatory elements in the caveolin-1 gene promoter 34 and our previous data in vitro, 15 rosuvastatin may exert its effect through transcriptional regulation of caveolin-1 expression. This does not exclude potential additional effects of the drug to enhance NOS signaling in vivo or other effects of the statin on HR or BP variability independent of NOS regulation. From our analysis in whole-tissue extracts, caveolin-1 downregulation is presumed to be at the endothelial cell level but could be in smooth muscle or other cell type(s). Unlike our previous observations in cultured endothelial cells, statin treatment had no effect in the control (ie, low LDL cholesterol) condition. Whether this is because of specific biological parameters in vivo or simply the consequence of a lesser sensitivity to detect a decrease from whole-tissue extracts with a lower caveolin pool in normocholesterolemic animals remains undetermined.
Notably, the hemodynamic improvements with rosuvastatin were observed despite the persistence of high plasma LDL cholesterol. This is in keeping with the clinical beneficial effects observed with other statins regardless of cholesterol level, 35 which add to the growing body of evidence suggesting that statins confer a therapeutic benefit beyond lipid lowering. 36, 37 The effect on BP demonstrated in our study would seem to be relevant to the cardiovascular benefit in patients, because statins can reduce BP in humans. 38, 39 Restoration of vagal and NOS-mediated regulation with statins would be particularly important in high-risk (including hypercholesterolemic) patients, given the adverse prognostic impact of altered HR and BP variability. 2 Whether such benefit might be extended to patients experiencing HR and BP disorders from causes other than dyslipidemia (such as heart failure 40, 41 ) will require further testing. Figure 2 . Caveolin-1 levels were higher in cardiac and aortic extracts from apoE Ϫ/Ϫ mice. Rosuvastatin had no significant effect on caveolin-1 levels in control mice but reduced its abundance back to control levels in both tissues of apoE Ϫ/Ϫ mice. *PϽ0.05 vs C57Bl/6; #PϽ0.05 vs apoE Ϫ/Ϫ without rosuvastatin treatment. Figure 6 . Relationship between aortic caveolin-1 expression and BP variability. Mean aortic caveolin-1 protein levels (expressed as fold increase over levels in control mice) were plotted against mean SBP variability in VLF band from 4 groups of mice (nϭ4 to 8 in all 4 groups). There was a strong correlation (yϭ5.25xϩ47.51, R 2 ϭ0.78) between aortic caveolin-1 expression and VLF energy band of SBPV. C57Bl/6 (ⅷ), apoE Ϫ/Ϫ (⅙), C57Bl/6 plus rosuvastatin ('), and apoE Ϫ/Ϫ plus rosuvastatin ().
